miR-376a inhibits breast cancer cell progression by targeting neuropilin-1 NR
Authors Zhang L, Chen Y, Wang H, Zheng X, Li C, Han Z
Received 7 May 2018
Accepted for publication 18 June 2018
Published 30 August 2018 Volume 2018:11 Pages 5293—5302
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 3
Editor who approved publication: Dr Federico Perche
Lansheng Zhang,1,2 Yanwei Chen,3 Hui Wang,3 Xia Zheng,2 Caihong Li,2 Zhengxiang Han3
1Department of Radiation Oncology, Shandong Cancer Hospital Affiliated to Shandong University, Jinan, People’s Republic of China; 2Department of Radiation Oncology, the Second Affiliated Hospital of Xuzhou Medical University, Xuzhou, People’s Republic of China; 3Department of Oncology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, People’s Republic of China
Background: The roles and related mechanism of miR-376a in breast cancer cell progression are unclear.
Methods: Kaplan-Meier plotter analysis was used to analyze the correlation between miR-376a and the overall survival (OS) of breast cancer patients. Quantitative reverse transcription polymerase chain reaction (qRT-PCR) was performed to detect miR-376a level in breast cancer cells. Cell viability, transwell migration and invasion, and cell apoptosis were constructed to investigate the effects of miR-376a on breast cancer cells. Luciferase reporter and RNA immunoprecipitation (RIP) were used to explore the targeting of miR-376a on NRP-1.
Results: miR-376a expression was positively correlated with the overall survival of breast cancer patients, and significantly decreased in breast cancer cells. Functionally, miR-376a overexpression suppressed cell proliferation, migration and invasion, and promoted cells apoptosis. Additionally, miR-376a could directly target NRP-1 and exerted its effect through NRP-1.
Conclusion: miR-376a could suppress breast cancer cell progression via directly targeting NRP-1.
Keywords: miR-376a, NRP-1, breast cancer, Wnt/β-catenin migration
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]